Change of Director's Interest Notice
Released
Released
Announcement PDF
Appendix 3Y
Change of Director's Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director's Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX
becomes ASX's property and may be made public.
Introduced 30/09/01
Amended 01/01/11
Name of entity
Paradigm Biopharmaceuticals Limited
ABN
94 169 346 963
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for
the purposes of section 205G of the Corporations Act.
Name of director
Paul Rennie
Date of last notice
05 December 2024
Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be
disclosed in this part.
Direct or indirect interest
(1) Direct
(2) Indirect
(3) Indirect
(4) Indirect
(5) Direct
(6) Indirect
Nature of indirect interest
(including registered holder)
(1) N/A
(2) SMSF
(3) FT
(4) SMSF
(5) N/A
(6) SMSF
Date of change
(1) N/A
(2) N/A
(3) N/A
(4) 20 December 2024
(5) N/A
(6) N/A
+
See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
Appendix 3Y
Change of Director's Interest Notice
No. of securities held prior to change
(1) 200,000 - FULLY PAID ORDINARY SHARES
(2) 10,767,843 - FULLY PAID ORDINARY SHARES
(3) 600,000 - FULLY PAID ORDINARY SHARES
(4) NIL - PERFORMANCE RIGHTS EXP
20/12/2027
(5) 8,545,848 - FULLY PAID ORDINARY SHARES
(6) 613,059 - FULLY PAID ORDINARY SHARES
Class
(1) FULLY PAID ORDINARY SHARES
(2) FULLY PAID ORDINARY SHARES
(3) FULLY PAID ORDINARY SHARES
(4) PERFORMANCE RIGHTS EXP 20/12/2027
(5) FULLY PAID ORDINARY SHARES
(6) FULLY PAID ORDINARY SHARES
Number acquired
(1) NIL
(2) NIL
(3) NIL
(4) 1,700,000 - PERFORMANCE RIGHTS EXP
20/12/2027
(5) NIL
(6) NIL
Number disposed
(1) NIL
(2) NIL
(3) NIL
(4) NIL
(5) NIL
(6) NIL
Value/Consideration
(1) N/A
(2) N/A
(3) N/A
(4) NIL - PERFORMANCE RIGHTS EXP
20/12/2027
(5) N/A
(6) N/A
+
See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 2
Appendix 3Y
Change of Director's Interest Notice
No. of securities held after change
(1) 200,000 - FULLY PAID ORDINARY SHARES
(2) 10,767,843 - FULLY PAID ORDINARY SHARES
(3) 600,000 - FULLY PAID ORDINARY SHARES
(4) 1,700,000 - PERFORMANCE RIGHTS EXP
20/12/2027
(5) 8,545,848 - FULLY PAID ORDINARY SHARES
(6) 613,059 - FULLY PAID ORDINARY SHARES
Nature of change
(1) N/A
(2) N/A
(3) N/A
(4) Employee Performance Rights Plan
(5) N/A
(6) N/A
Part 2 - Change of director's relevant interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be
disclosed in this part.
Detail of contract
N/A
Nature of interest
N/A
Name of registered holder
(if issued securities)
N/A
Date of change
N/A
No. and class of securities
to which interest related
prior to change
N/A
Interest acquired
N/A
Interest disposed
N/A
Value/Consideration
N/A
Interest after change
N/A
Part 3 - +Closed period
Were the interests in the securities or
contracts
detailed above traded during a
+closed period
where prior written clearance
was required?
No
If so, was prior written clearance provided to
allow the trade to proceed during this period?
N/A
If prior written clearance was provided, on
what date was this provided?
N/A
+
See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 3
Share your feedback
Discover